Japan · Delayed Price · Currency is JPY PHC Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw strong BGM and diabetes management growth, offsetting declines in diagnostics and life sciences, with FX losses impacting net profit. Full-year guidance remains unchanged, with a conservative Q4 outlook due to market risks and inventory adjustments.
-
Operating profit forecast was revised upward despite FX losses and persistent US tariff impacts. BGM margins improved on price hikes and cost controls, while diagnostics and life sciences face ongoing headwinds. CGM business transfer is on track, with no impairment loss recognized.
-
First quarter revenue declined 1.6% year-on-year due to FX, but operating profit surged 89.6% on strong BGM sales in developed markets. Full year and dividend forecasts remain unchanged, with tariff and FX risks closely monitored.
Fiscal Year 2025
-
FY2024 saw revenue and profit growth, driven by healthcare IT and cost reductions, despite weak capital investment in diagnostics and life sciences. FY2025 guidance anticipates modest revenue growth but lower profit due to restructuring and tariff risks, with dividends maintained.
-
Q3 revenue and profit rose year-over-year, led by CGM growth, e-prescription demand, and cost reductions. Full-year operating profit guidance was raised, but revenue guidance held steady due to slow market recovery in Europe and the US. Margin improvements and new product launches support a positive outlook.
-
Second quarter revenue and profits grew year-over-year, driven by FX gains and healthcare IT. Full-year guidance and dividend remain unchanged, with stronger performance expected in the second half amid some market uncertainties.
-
Q1 FY24 revenue and operating profit rose year-on-year, driven by M&A and FX gains, but FX losses led to a net loss. Full-year guidance and dividend plan remain unchanged, with growth expected in the second half from new product launches and market recovery.